Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. Its therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells.
|HQ||Philadelphia, PA, US||Map|
Net income (Q1, 2021)
EBIT (Q1, 2021)
Market capitalization (17-Sept-2021)
Closing stock price (17-Sept-2021)
Cabaletta Bio has 281 Twitter Followers. The number of followers has increased 2.6% month over month and increased 10.6% quarter over quarter
When was Cabaletta Bio founded?
Cabaletta Bio was founded in 2017.
Who are Cabaletta Bio key executives?
Cabaletta Bio's key executives are Steven Nichtberger, Gwendolyn Binder and Catherine Bollard.
How many employees does Cabaletta Bio have?
Cabaletta Bio has 19 employees.
Who are Cabaletta Bio competitors?
Competitors of Cabaletta Bio include Lupagen, Cristcot and LQT Therapeutics.
Where is Cabaletta Bio headquarters?
Cabaletta Bio headquarters is located at Cira Centre, 2929 Arch St #600, Philadelphia.
Where are Cabaletta Bio offices?
Cabaletta Bio has an office in Philadelphia.
How many offices does Cabaletta Bio have?
Cabaletta Bio has 1 office.
Receive alerts for 300+ data fields across thousands of companies